today's Pick
US frees up another experimental Ebola drug
Publish Date: Aug 08, 2014
newvision
  • mail
  • img

WASHINGTON - US regulators loosened restrictions on a new experimental drug for treating Ebola, which may allow it to be tried on infected patients in West Africa, the company said yesterday.

The Canada-based company, Tekmira, said the US Food and Drug Administration changed the classification of its drug TKM-Ebola from full clinical hold to partial hold.

"This action enables the potential use of TKM-Ebola in individuals infected with Ebola virus," said a company statement.

Tests on monkeys have shown the drug provided 100 percent protection from an otherwise lethal dose of Ebola, the company said.

West Africa is experiencing the largest outbreak of Ebola in history. The virus has killed 932 people of more than 1,700 infected, and the disease continues to spread.

"This current outbreak underscores the critical need for effective therapeutic agents to treat the Ebola virus," said Mark Murray, CEO and president of Tekmira Pharmaceuticals.

"We recognize the heightened urgency of this situation, and are carefully evaluating options for use of our investigational drug within accepted clinical and regulatory protocols."

TKM-Ebola is being developed under a $140 million contract with the US Department of Defense's Medical Countermeasure Systems BioDefense Therapeutics Joint Product Management Office.

The drug, described as an anti-Ebola virus RNAi therapeutic, is designed to be given in multiple doses, which is not always practical in a mass outbreak.

However, there are no drugs on the market to treat Ebola and no vaccines against it.

The rapidly growing outbreak in West Africa has sped up the process of getting experimental therapies to market, though experts say it may be months before production can be scaled up and the drugs delivered to those in need.

The two American missionaries who were evacuated from Liberia in recent days were given a different experimental serum known as ZMapp.

Both Kent Brantly and Nancy Writebol are improving, but health authorities say it is too early to tell if the drug had anything to do with that.

Related Stories

Ebola discoverer says would sit next to victim

Too early to send experimental Ebola drug to Africa - Obama

 

The statements, comments, or opinions expressed through the use of New Vision Online are those of their respective authors, who are solely responsible for them, and do not necessarily represent the views held by the staff and management of New Vision Online.

New Vision Online reserves the right to moderate, publish or delete a post without warning or consultation with the author.Find out why we moderate comments. For any questions please contact digital@newvision.co.ug

  • mail
  • img
blog comments powered by Disqus
Also In This Section
In pictures: Bodies of slain UPDF soldiers return home
The bodies of the 10 UPDF soldiers killed in Somalia on Tuesday, were returned home on Thursday....
Somalia  condemns attack on AMISOM base
The Embassy of the Federal Republic of Somalia in Kampala, has condemned the Al-shaabab suicide attack on Tuesday that claimed 10 Ugandan peacekeepers and 46 militants....
Doctor suspected of abortion, petitions court to redeem image
A medical doctor paraded by Police last year and suspected of procuring an abortion, has petitioned court to compel government to redeem his image....
Earth has three trillion trees: study
There are about three trillion trees on Earth, roughly 422 for every person and eight times more than previously estimated, researchers said Wednesday, admitting surprise....
New Vision to serialize Wavamuno’s book
Starting Friday 4th September 2015 the New Vision will run a three part serialisation of the book, “Gordon B.K. Wavamunno...
The World Health Organization on Thursday announced that Liberia, recently ravaged by Ebola, was free of the virus, 42 days after the last confirmed case passed a second negative test....
Are poor parliamentary debates a result of removal of school debates?
Yes
No
Can't Say
follow us
subscribe to our news letter